Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy – insights.citeline.com

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.
Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.

source
This is a newsfeed from leading technology publications. No additional editorial review has been performed before posting.